Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

TAC-T Cell Activation, Transduction & Expansion Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Overcoming the challenges of therapy-induced toxicities, limited solid tumor penetration, and variable T-cell functionality during manufacturing requires innovative solutions. Creative Biolabs' TAC-T Cell Activation, Transduction & Expansion Service addresses these hurdles by integrating proprietary TAC technology with serum-free, precision-controlled processes. This service leverages the native TCR signaling machinery to deliver a physiologically optimized workflow, providing clients with T cell products engineered for superior safety, enhanced tumor infiltration, and consistent, scalable potency for advanced solid tumor therapeutics.

Introduction

While CAR-T cell therapy has achieved remarkable success in hematological malignancies, its clinical application is significantly hampered by serious toxicities, most notably cytokine release syndrome (CRS), and limited efficacy in solid tumors. The T cell antigen coupler (TAC), a novel chimeric receptor, is engineered to co-opt the complete endogenous T cell receptor (TCR)-CD3 complex for signaling. TAC-engineered T cells exhibit robust, antigen-specific anti-tumor activity in both solid and liquid tumor xenograft models.

Fig.1 TAC architecture emulates the TCR-CD3: co-receptor assembly. (OA Literature) Fig.1 TAC construct mimics the formation of TCR-CD3: co-receptor complex.¹

TAC-T Cell Activation, Transduction & Expansion Service at Creative Biolabs

Creative Biolabs offers a fully integrated, end-to-end development service for TAC therapies. Our pipeline applies systematic molecular optimization and cellular conditioning to engineer T-cell products with the precise mechanical resilience and metabolic fitness necessary for robust clinical efficacy.

What We Can Offer

Our platform offers comprehensive T cell engineering services, from precise activation and high-efficiency viral/non-viral transduction to phenotype-guided expansion, delivering robust, clinically relevant cell therapy products.

Featured services of TAC-T cell activation, transduction & expansion service at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Antigen Information: Sequence data or specific epitopes for the target tumor-associated antigen.
scFv/Ligand Sequences: Existing binder sequences or specific affinity requirements for the recruitment domain.

Key Steps:

Workflow of TAC-T cell activation, transduction & expansion service at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Engineered TAC-T Cell Product: Cryopreserved, ready-to-use cell vials.
Characterization Report: Detailed data on transduction efficiency, phenotype, and potency.
Optimization Data: Insights into the affinity-tuning and expansion kinetics of your specific construct.

Key Advantages

Physiological Activation for Enhanced Safety: Our bead-free activation mimics natural antigen presentation, reducing cytokine release syndrome risk and preventing early T cell exhaustion. This yields a healthier, less differentiated T-cell pool for safer and more effective therapeutic engineering.
High-Efficiency, Low-Impact Genetic Transduction: We provide both viral and non-viral gene delivery options that maintain high viability and editing efficiency. This flexibility supports diverse research and clinical goals while improving safety profiles by minimizing risks linked to traditional viral vectors.
Tailored Expansion for Optimized Product Phenotype: Using custom cytokine and culture protocols, we enrich durable T-cell subsets like memory stem cells and enhance metabolic and mechanical fitness. This boosts tumor infiltration and long-term function in challenging tumor microenvironments.

FAQs

Q1: How does TAC-T activation differ from traditional CAR-T activation?

A1: Unlike CAR-T cells, which rely on synthetic, constitutively active signaling domains, TAC-T cells are engineered to harness the complete endogenous TCR/CD3 complex and co-receptors for signal transduction. This approach preserves native signaling dynamics and natural feedback mechanisms, leading to more physiological activation kinetics, a reduced risk of tonic signaling, and potentially lower toxicity profiles.

Q2: Is your service compatible with non-viral genetic engineering methods?

A2: Our platform is highly versatile and supports multiple gene delivery modalities. In addition to standard lentiviral transduction, we provide optimized non-viral methods including mRNA electroporation for transient expression and advanced transposon-based systems for stable genomic integration, catering to diverse research and clinical development strategies.

Why Choose Us?

Creative Biolabs pioneers mechanoimmunology-based cell therapy. Our TAC-T platform uniquely optimizes "Affinity Tuning" and leverages mechanical signaling, enabling effective solid tumor penetration while minimizing cytokine release syndrome (CRS). By co-opting native TCR machinery, we achieve enhanced tumor infiltration and local expansion compared to conventional CD28/4-1BB signaling systems.

Customer Reviews

"Utilizing Creative Biolabs' TAC-T transduction platform was instrumental in generating high-affinity variants that effectively resist the functional exhaustion commonly associated with CAR-based constructs."

— Prof. R***rt K.

"Creative Biolabs' TAC-T expansion service proved critical for enabling the sustained persistence of our engineered T cells within immunosuppressive tumor niches."

— Dr. Al***n M.

"The TAC-T activation reagents from Creative Biolabs markedly enhanced the safety of our lead therapeutic candidate, demonstrating minimal CRS signatures in primary cellular assays."

— Sarah L***s.

How to contact us?

Creative Biolabs provides a premier TAC-T Cell Activation, Transduction & Expansion Service, incorporating cutting-edge mechanoimmunology and metabolic engineering insights. Our approach targets the optimal physiological activation window for T cells, enabling partners to develop safer, more durable, and more potent therapies for solid tumors.

Reach out to our team to explore collaboration opportunities and discuss your specific project needs.

Reference

Helsen, Christopher W et al. "The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity." Nature communications vol. 9,1 3049. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1038/s41467-018-05395-y

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.